Objective: Endoleaks are one of the unique complications seen after endovascular repair of thoracic aortic aneurysms (TEVAR). This investigation was performed to evaluate the incidence and determinants of endoleaks, as well as the outcomes of secondary interventions in patients with endoleaks, after TEVAR. Methods: Over a 6-year period, 105 patients underwent TEVAR in the context of pivotal Food and Drug Administration trials with the Medtronic Talent (n ‫؍‬ 64) and Gore TAG (n ‫؍‬ 41) devices. The medical and radiology records of these patients were reviewed for this retrospective study. Of these, 69 patients (30 women and 39 men) had follow-up longer than 1 month and were used for this analysis. The patients were evaluated for the presence of an endoleak, endoleak type, aneurysm expansion, and endoleak intervention. 
As endovascular repair of abdominal aortic aneurysms (EVAR) has become an accepted alternative to open abdominal aortic aneurysm (AAA) repair, endovascular techniques are now being used to treat thoracic aortic aneurysms (TAAs). [1] [2] [3] [4] [5] [6] [7] [8] [9] This endovascular approach (TEVAR) offers a subset of TAA patients a less invasive technique to exclude their aneurysms. [3] [4] [5] [6] [7] [8] [9] It has also altered the way patients are followed up after TAA repair. Unlike the minimal imaging required after open surgical repair, patients undergoing endovascular repair of TAAs require lifelong postoperative surveillance imaging. [3] [4] [5] [6] [7] [8] [9] [10] Although the imaging modality and interval after aneurysm repair are topics that are being debated, some form of surveillance imaging is needed to detect some of the unique complications of TEVAR. These include stent graft migration and endoleak formation. [10] [11] [12] Although the detection and management of endoleaks after EVAR have been well described, less is known about endoleaks after TEVAR. [10] [11] [12] [13] [14] This investigation was performed to evaluate the incidence and determinants of endoleaks and the outcomes of secondary interventions in patients with endoleaks after endovascular repair of TAAs.
METHODS
Approval by the institutional review board was granted for this retrospective study. A review of consecutive clinical cases and follow-up imaging studies was performed on patients who underwent TEVAR. These procedures were performed in the context of Food and Drug Administration trials with the Medtronic Talent (Medtronic, Minneapolis, Minn) and the Gore TAG (Gore, Flagstaff, Ariz) devices.
Review of the medical and radiology records of TAA patients who underwent TEVAR between April 1999 and May 2006 yielded a study group of 105 patients. Of these, 69 patients (30 women and 39 men) had follow-up longer than 1 month and were used for this analysis. The reasons for exclusion in the 36 patients with follow-up less than a month were death (14) , loss to follow-up (10) , and imaging that was not available for review (12) . Of the deaths, one was procedure related, four were cardiac related, four were pulmonary, and one was caused by stroke; four causes were unknown. The mean age was 72.9 Ϯ 9.2 years. The Talent device was used in 41 (59%) patients, and the Gore TAG device was used in 28 (41%) patients. After aneurysm repair, imaging by triple-phase computed tomographic angiography (CTA) was performed at 1, 6, and 12 months after stent graft implantation and annually thereafter for the life of the patient. More frequent examinations were performed when clinically indicated.
CTA was performed with multidetector scanners (General Electric HISPEED CTi or LightSpeed Qxi; GE Medical Systems, Milwaukee, Wis). The three-phase CTA consisted of a noncontrast scan through the chest and upper abdomen, followed by a chest and abdomen CTA using 120 mL of nonionic contrast. A 2-minute delayed computed tomographic (CT) scan was then performed again through the chest and upper abdomen.
The patients were evaluated for the presence of an endoleak, endoleak type, aneurysm expansion, and endoleak intervention. The CTA examinations were evaluated on GE workstations with multiplanar reformatting capabilities to classify the endoleak type. Type I endoleaks were classified on CTA on the basis of the location of the endoleak in contiguity with the proximal or distal attachment site, as well as early filling of the endoleak sac on the CTA (Fig 1, A) . Endoleaks were classified as type II endoleaks if the endoleak sac could not be seen communicating with the distal or proximal attachment site or if there was delayed enhancement of the endoleak sac (Fig 1, B) . If an endoleak was associated with junctional separation of two stent graft sections, it was called a type III endoleak ( Figure 1, C and D) . For comparison of changes in aortic sac diameter, all CTAs were further evaluated by a core facility (Medical Metrx Solutions, Inc, West Lebanon, NH) to allow for standardized measurements of maximal aortic sac diameter.
Data are expressed as mean and standard deviation. Comparison of continuous variables was made by using the Student t test for independent variables. Categorical variables were compared by using the Fisher exact test. Differences were considered significant if the two-tailed P value was Ͻ.05.
RESULTS
The mean follow-up time for the patient cohort was 17.3 Ϯ 14.7 months (range, 3-71 months). Endoleaks were detected in 29% (20/69) of patients. Forty percent (8/20) were type I endoleaks, 35% (7/20) were type II, 20% (4/20) were type III, and 5% (1/20) had more than one type of endoleak. All but two endoleaks (90%; 18/20) were detected on the initial postoperative CT scan at 30 days. Two endoleaks (10%; 2/20) were detected late. One type II endoleak was detected during the 6-month follow-up CT, whereas a type III endoleak was detected at 2 years in a patient who previously was without an endoleak.
When patients who developed endoleaks were compared with those who did not, there was a similar age distribution and prevalence of common medical comorbid conditions (Table I ). There were, however, significantly more male patients in the endoleak group (80% vs 47%; P ϭ .016). Follow-up in patients with endoleaks was longer (21.6 Ϯ 15.3 months) when compared with that in those without endoleaks (15.6 Ϯ 14.2 months), although this failed to reach statistical significance (P ϭ .125; Table I ).
The endoleak group had more extensive aneurysms and had significantly larger aneurysms at the time of intervention (69.4 Ϯ 10.5 mm vs 60.6 Ϯ 11.0 mm; P ϭ .003; Table II ). The section of aorta treated by stent grafts was also significantly longer in endoleak patients (254.3 Ϯ 61.0 mm vs 192.9 Ϯ 58.8 mm; P ϭ .0004). In addition, the number of stents used was significantly higher for endoleak patients when compared with those who did not develop endoleaks (3.7 Ϯ 1.3 vs 2.2 Ϯ 1.0; P Ͻ .0001).
Aneurysm morphology, saccular or fusiform, was not significantly different; 20% of endoleak patients and 35% of patients without endoleaks had saccular morphology (P ϭ .265). Although more patients in the endoleak group received the Talent device (75% vs 53%) compared with the TAG device, this too failed to reach statistical significance (P ϭ .111; Table II) .
During follow-up, the maximum aneurysm diameter in all endoleak patients decreased an average of 0.13 Ϯ 7.2 mm (range, Ϫ13 to ϩ17 mm), compared with a decrease of 2.89 Ϯ 9.1 mm (range, Ϫ44.7 to ϩ9.9 mm) for those with no endoleak (P ϭ .141; Table II) . For all patients, the mean changes in maximal aortic diameter were calculated by comparing the baseline aortic diameter with the maximal diameter at last follow-up, irrespective of endoleak treatment. For patients with type I endoleaks, despite initial increases (Fig 1, A) , after endoleak treatment, the mean maximum aneurysm diameter of all patients decreased an average of 2.9 Ϯ 7.7 mm (Table III) . This ranged from an increase in diameter of 6.4 mm to a decrease in diameter of 13 mm. Patients with type II endoleaks had an increase in their aneurysm size by a mean of 2.6 Ϯ 7.3 mm (range, Ϫ4.4 to ϩ17 mm). Patients with type III endoleaks had a mean decrease in aneurysm size of 0.78 Ϯ 3.1 mm (range, Ϫ3.3 to ϩ 3.3 mm). The change in aneurysm maximal diameter was not statistically different when patients with no endoleak were compared with those with type I (P ϭ .998), type II (P ϭ .136), or type III (P ϭ .649) endoleaks (Table III) . Furthermore, the difference in the change in aneurysm diameter between patients with type I and type II endoleaks was also not statistically significant (P ϭ .209). The difference between patients with type I and type III (P ϭ .648) endoleaks and the difference between those with type II and type III (P ϭ .413) endoleaks was also not statistically significant (Table III) .
No open conversions where performed for the treatment of endoleaks. Endovascular techniques were success-ful in treating endoleaks in four (50%) patients with type I endoleaks. In the one patient with type I, II, and III endoleaks, endovascular techniques were used to successfully treat the type III endoleak. Details of these remedial procedures are shown in Table IV . In 12% (1/8) of patients, endovascular techniques were unsuccessful in treating the type I endoleak. This patient had successful treatment of a proximal leak but has had persistence of the distal leak and continues to be observed because he refused further intervention. Spontaneous resolution of type I endoleaks occurred in three (38%) patients with small distal endoleaks.
Despite initial increases in sac diameter in patients with type I endoleaks, those who underwent successful treatment went on to have progressive decreases in sac diameter after treatment (Fig 2, A) . The one patient who had resolution of the proximal leak with a persistent distal leak initially experienced a decrease in sac diameter but had an increase at last follow-up (Fig 2, A) . Of the three patients who had spontaneous resolution of the type I endoleak, one had continued decreases, one had stabilization of the sac, and one continued to have sac expansion (Fig 2, A) .
All of the patients with type II endoleaks continue to be observed, and no secondary interventions have been performed on these patients. Spontaneous thrombosis has occurred in 29% (2/7) of patients with type II endoleaks according to follow-up CTA. Despite thrombosis, however, sac regression has not occurred in these patients (Fig 2, B ) . None of the type III endoleaks resolved spontaneously. As discussed, one patient with complex endoleaks was treated and experienced resolution of the type III leak but had continued type I and II leaks. Despite persistence, most patients with type III endoleaks have had sac stabilization or regression during follow-up (Fig 2, C ) . The one patient who developed a late type III endoleak has had sac expansion since this leak appeared.
DISCUSSION
Although a great deal has been written about endoleaks after EVAR, less is known about endoleaks after TEVAR. [10] [11] [12] [13] [14] Earlier series involving stent graft repair of TAAs have shown that endoleaks occur in 5% to 20% of patients, which is similar to the endoleak incidence after EVAR. [3] [4] [5] [6] [7] [8] [9] [10] Management has generally consisted of aggressive endovascular repair of type I and type III endoleaks, with observation of type II endoleaks. [3] [4] [5] [6] [7] [8] [9] [10] Endoleaks after TEVAR were not uncommon in our series, occurring in 29% of patients. Although there have been some data to suggest factors that may be predictive of sac expansion after EVAR, little has been published regarding the factors that are predictive of the development of endoleaks, especially in patients after TEVAR. 15, 16 Consistent with these studies, the presence of an endoleak led to significantly less sac regression (Ϫ0.13 Ϯ 7.2 mm vs Ϫ2.89 Ϯ 9.1 mm; P ϭ .232; Table II ). Patients without endoleaks continued to have sac regression during follow-up (Fig 3) , although this was less consistent with patients who developed endoleaks (Fig 2) .
In this study, several differences between the group of patients who developed endoleaks and those who did not deserve further discussion. Although patients with and without endoleaks were similar with respect to age distribution and the prevalence of medical comorbidities, there was a significantly larger proportion of male patients in the endoleak group (80% vs 47%; P ϭ .016; Table I ). Furthermore, patients who developed endoleaks had more extensive aneurysms at the time of repair. Preoperative sac diameter was significantly larger in endoleak patients (69.4 Ϯ 10.5 mm vs 60.6 Ϯ 11.0 mm; P ϭ .003; Table II) . Additionally, significantly more stents (3.7 Ϯ 1.3 vs 2.2 Ϯ 1.0; P Ͻ .0001) and a greater length of stent coverage (254.3 Ϯ 61.0 mm vs 192.9 Ϯ 58.8 mm; P ϭ .0004) were required to treat patients in the endoleak group.
These data suggest that patients requiring extensive aortic coverage with multiple stents are at increased risk for endoleak and perhaps may not do as well in the long term as a result. In fact, there was a larger proportion of patients with saccular morphology in the group without endoleaks (35% vs 20%), although this failed to reach statistical significance (P ϭ .265; Table II ). Data also suggest that using devices that are longer instead of multiple short devices may provide superior results by decreasing the incidence of postoperative endoleak. This is illustrated by the larger proportion of Talent stents used in patients who developed endoleaks vs those who did not (75% vs 53%), although this also failed to reach statistical significance (P ϭ .111). The Talent stent has shorter lengths than the TAG device and necessitates multiple stents more often. With the newer Talent devices, which are longer, it is anticipated that this will not be as much of an issue. Similar to the approach taken after EVAR, type I endoleaks were treated by using endovascular techniques. These techniques were successful in four of eight patients (Table IV) . After attempted endovascular repair, one of the eight type I endoleak patients continued to demonstrate an endoleak. The contribution of type I endoleaks on failure of sac regression is well illustrated in Fig 2, A; satisfactory repair of type I endoleaks results in dramatic sac regression for most patients. This is likely responsible for the overall decrease in sac diameter (Ϫ0.78 Ϯ 3.1 mm) in this patient population (Table III) . The virulence of type I endoleaks was demonstrated by one of our patients who experienced fatal rupture of his aneurysm after an unsuccessful attempt at endoleak remediation. This patient represents the only aneurysm-related death in the cohort but was not included in the overall analysis because he had follow-up less than 1 month.
Despite overall aneurysm enlargement (2.6 Ϯ 7.3 mm), as with other series, type II endoleaks were not actively treated. In addition, 29% (2/7) of them spontaneously thrombosed. After thrombosis, these aneurysms continued to grow, one by 17 mm at last follow-up (Fig 2, B) . In this patient, despite no further evidence of endoleak, the sac continues to expand and is largely responsible for the overall increase in aneurysm size for the type II endoleak group. Treatment of type II endoleaks via transarterial or translumbar embolization can be considerably more difficult than treatment of type II endoleaks after AAA repair. This is because collateral circulation in the thoracic aorta is not developed as well as in the abdominal aorta. In addition, accessing the endoleak sac in TAA patients by using a direct puncture often involves traversing lung, which has a much greater risk associated with it than translumbar embolization of endoleaks in AAA patients. 17 Despite these risks, with continued sac expansion it is uncertain whether the watchful waiting approach to type II endoleaks that has been advocated is warranted in TAA patients.
Type III endoleaks were the least common and could occur late. One patient was treated with a junctional stent, with resolution (Table IV) . Although most type III endoleaks remained persistent, these patients continued to have sac regression over time (Fig 2, C) .
Limitations to this study exist. The absolute numbers in each category were low, thus contributing to type II error and failure to recognize significant contributors to endoleak formation and sac expansion. CTA was used to diagnose and to classify the endoleaks in this series. On the basis of findings of endoleaks after AAA, CTA classification of endoleaks is less accurate than classification with diagnostic angiography. Furthermore, magnetic resonance angiography or intravascular ultrasonography may also provide insight into the classification of endoleaks and might be considered. Some of the patients classified as having type II endoleaks on CTA could have small type I or type III endoleaks. Because the aneurysms are continuing to grow, these other modalities may shed some light on this possibility and allow for further treatment.
In conclusion, this series demonstrates that endoleaks occur after TEVAR with an incidence similar to that seen after EVAR. The presence of an endoleak is associated with less sac regression. Patients with larger, more extensive aneurysms are at increased risk for the development of endoleaks. Type I endoleaks are often amenable to repair using endovascular techniques, with subsequent sac regression. Patients with type II endoleaks tend to continue to have sac expansion, and consideration should be given to further evaluating the nature of the endoleak to determine whether it is amenable to treatment. Regardless, all patients after TEVAR should be followed up closely and consistently to identify endoleaks so that treatment, when indicated, can be offered to allow for optimal outcomes in these patients.
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